A Phase 3 interventional study of Axitinib (AG-013736) and Sorafenib in Kidney Neoplasms, sponsored by Pfizer. Completed at 125 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-06.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing axitinib in Kidney Neoplasms — 3 open to participants now, 3 under way, 1 of them phase 3. Axitinib · Kidney Neoplasms.
Among the 12 studies testing axitinib in Kidney Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 3, and was the 4th registered.
969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.
Browse Kidney Neoplasms studies →3 of the 12 studies testing axitinib in Kidney Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Stephanie Berg · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18+
By country, each count listing its studies:
Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 173 Kidney Neoplasms studies recruiting now, 133 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 4
First in 2006; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 492 is above the median of 46 across 668 interventional studies indexed under Kidney Neoplasms.
Median enrollment 54 across the 12 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
21 studies in Kidney Neoplasms by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 15 (79%) have results posted.
Among the 21 studies in Kidney Neoplasms by Pfizer, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2009, is one of 6 in phase 3, and was the 12th registered.
Pfizer’s Kidney Neoplasms studies by the year they started, since 2003.
1 of the studies testing axitinib in Kidney Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123090Stephanie BergA Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing axitinib in Kidney Neoplasms, from their registry updates:
Among Pfizer’s 21 in Kidney Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Axitinib (AG-013736)
Drug: Sorafenib
axitinib will be given at a starting dose of 5 mg BID with continuous dosing
sorafenib will be given at a dose of 400 mg BID continuous dosing
Progression Free Survival (PFS): First-Line Participants
Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease \[PD\]), or from adverse event (AE) data (where outcome was "Death"). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is \>= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.
Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
Progression Free Survival (PFS): Second-Line Participants
Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease \[PD\]), or from adverse event (AE) data (where outcome was "Death"). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is \>= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.
Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
Percentage of Participants With Objective Response (OR): First-Line Participants
Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
Percentage of Participants With Objective Response (OR): Second-Line Participants
Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
Duration of Response (DR): First-Line Participants
Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
Duration of Response (DR): Second-Line Participants
Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
Overall Survival (OS): First-Line Participants
Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
Time frame: Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
Overall Survival (OS): Second-Line Participants
Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
Time frame: Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): First-Line Participants
FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).
Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): Second-Line Participants
FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).
Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): First-Line Participants
FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).
Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): Second-Line Participants
FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).
Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: First-Line Participants
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: Second-Line Participants
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): First-Line Participants
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.
Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): Second-Line Participants
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.
Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
First-line participants included all treatment-naive participants with metastatic renal cell cancer (mRCC) from global and second-line participants included all previously-treated Asian participants with mRCC.
| Milestone | Axitinib (First-line Participants) | Sorafenib (First-line Participants) | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|---|---|
| Started | 192 | 96 | 135 | 69 |
| Treated | 189 | 96 | 135 | 69 |
| Participants from china (excluded from safety analysis) | 16 | 8 | 124 | 64 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 192 | 96 | 135 | 69 |
| Withdrew: Death | 116 | 63 | 8 | 3 |
| Withdrew: Participant refused continued treatment for reason other than adverse events | 11 | 5 | 1 | 0 |
| Withdrew: Global deterioration of health status | 2 | 0 | 0 | 0 |
| Withdrew: Objective progression or relapse | 6 | 2 | 0 | 0 |
| Withdrew: Other | 26 | 15 | 1 | 2 |
| Withdrew: Lost to follow-up | 11 | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 1 | 0 |
| Withdrew: Data not disclosed due to lack of hgrac filings | 16 | 8 | 124 | 64 |
| Withdrew: Randomized but not treated | 3 | 0 | 0 | 0 |
Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease \[PD\]), or from adverse event (AE) data (where outcome was "Death"). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is \>= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.
| months | Axitinib (First-line Participants) | Sorafenib (First-line Participants) |
|---|---|---|
| Progression Free Survival (PFS): First-Line Participants | 10.1 (7.2 to 12.1) | 6.5 (4.7 to 8.3) |
Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease \[PD\]), or from adverse event (AE) data (where outcome was "Death"). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is \>= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.
| months | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|
| Progression Free Survival (PFS): Second-Line Participants | 6.5 (4.7 to 9.1) | 4.8 (3.0 to 6.5) |
Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
| percentage of participants | Axitinib (First-line Participants) | Sorafenib (First-line Participants) |
|---|---|---|
| Percentage of Participants With Objective Response (OR): First-Line Participants | 32.3 (25.7 to 39.4) | 14.6 (8.2 to 23.3) |
Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
| percentage of participants | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|
| Percentage of Participants With Objective Response (OR): Second-Line Participants | 23.7 (16.8 to 31.8) | 10.1 (4.2 to 19.8) |
Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| months | Axitinib (First-line Participants) | Sorafenib (First-line Participants) |
|---|---|---|
| Duration of Response (DR): First-Line Participants | 14.7 (11.0 to NA) | 14.3 (11.3 to NA) |
Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| months | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|
| Duration of Response (DR): Second-Line Participants | NA (12.5 to NA) | 8.7 (4.1 to NA) |
Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
| months | Axitinib (First-line Participants) | Sorafenib (First-line Participants) |
|---|---|---|
| Overall Survival (OS): First-Line Participants | NA (18.1 to NA) | NA (18.1 to NA) |
Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
| months | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|
| Overall Survival (OS): Second-Line Participants | 17.2 (14.8 to NA) | 18.1 (12.1 to NA) |
FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).
| units on a scale | Axitinib (First-line Participants) | Sorafenib (First-line Participants) |
|---|---|---|
| C1 D1 | 43.869 ± 8.117 | 43.865 ± 6.723 |
| C2 D1 | 43.328 ± 7.630 | 43.969 ± 6.286 |
| C3 D1 | 43.366 ± 7.192 | 43.345 ± 6.878 |
| C4 D1 | 42.932 ± 7.566 | 42.926 ± 7.324 |
| C5 D1 | 43.211 ± 7.578 | 44.022 ± 6.714 |
| C6 D1 | 42.787 ± 8.098 | 42.344 ± 6.685 |
| C7 D1 | 42.474 ± 7.926 | 43.446 ± 6.931 |
| C8 D1 | 42.534 ± 7.510 | 44.077 ± 6.986 |
| C9 D1 | 42.778 ± 8.229 | 44.051 ± 7.234 |
| C10 D1 | 43.120 ± 7.966 | 44.018 ± 6.751 |
| C11 D1 | 43.264 ± 7.837 | 45.000 ± 6.130 |
| C12 D1 | 43.962 ± 7.243 | 45.318 ± 6.440 |
| C13 D1 | 44.141 ± 7.289 | 45.787 ± 6.526 |
| C14 D1 | 43.789 ± 7.985 | 45.459 ± 6.535 |
| C15 D1 | 44.176 ± 8.055 | 45.514 ± 5.914 |
| C16 D1 | 44.232 ± 7.515 | 46.000 ± 5.651 |
| C17 D1 | 43.897 ± 8.456 | 46.400 ± 6.262 |
| C18 D1 | 43.761 ± 8.019 | 45.357 ± 6.983 |
| C19 D1 | 43.737 ± 7.413 | 45.583 ± 7.366 |
| C20 D1 | 43.733 ± 7.605 | 44.333 ± 7.066 |
| C21 D1 | 45.417 ± 6.240 | 43.500 ± 7.687 |
| C22 D1 | 47.000 ± 5.985 | 45.833 ± 5.937 |
| C23 D1 | 47.571 ± 6.357 | 45.714 ± 6.651 |
| End of treatment | 39.052 ± 9.109 | 39.524 ± 8.896 |
| Follow-up | 39.683 ± 11.132 | 40.038 ± 9.897 |
FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).
| units on a scale | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|
| C1 D1 | 46.753 ± 6.692 | 47.470 ± 7.450 |
| C2 D1 | 46.217 ± 7.028 | 45.045 ± 7.478 |
| C3 D1 | 45.968 ± 7.237 | 45.684 ± 7.756 |
| C4 D1 | 45.060 ± 8.040 | 45.792 ± 7.762 |
| C5 D1 | 45.775 ± 7.797 | 46.125 ± 7.491 |
| C6 D1 | 45.407 ± 7.274 | 46.341 ± 7.213 |
| C7 D1 | 45.709 ± 8.263 | 45.053 ± 7.843 |
| C8 D1 | 45.169 ± 7.609 | 45.676 ± 9.357 |
| C9 D1 | 45.829 ± 7.442 | 45.970 ± 8.487 |
| C10 D1 | 45.608 ± 8.299 | 46.148 ± 8.156 |
| C11 D1 | 45.833 ± 7.599 | 47.227 ± 6.611 |
| C12 D1 | 45.797 ± 6.967 | 48.091 ± 6.414 |
| C13 D1 | 46.727 ± 7.307 | 47.600 ± 5.762 |
| C14 D1 | 47.740 ± 7.094 | 49.133 ± 5.235 |
| C15 D1 | 48.023 ± 6.297 | 49.308 ± 4.111 |
| C16 D1 | 48.184 ± 6.186 | 50.500 ± 3.989 |
| C17 D1 | 47.909 ± 6.866 | 49.000 ± 5.869 |
| C18 D1 | 48.138 ± 6.791 | 49.125 ± 5.139 |
| C19 D1 | 48.636 ± 5.206 | 48.571 ± 7.458 |
| C20 D1 | 48.810 ± 6.478 | 50.500 ± 4.637 |
| C21 D1 | 50.188 ± 5.588 | 50.000 ± 5.177 |
| End of treatment | 41.432 ± 9.188 | 42.889 ± 8.846 |
| Follow-up | 35.385 ± 7.795 | 38.583 ± 11.556 |
FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).
| units on a scale | Axitinib (First-line Participants) | Sorafenib (First-line Participants) |
|---|---|---|
| C1 D1 | 28.691 ± 5.392 | 29.653 ± 4.699 |
| C2 D1 | 28.728 ± 4.581 | 29.963 ± 3.817 |
| C3 D1 ( | 29.171 ± 4.093 | 29.750 ± 4.095 |
| C4 D1 | 28.577 ± 4.305 | 29.642 ± 4.244 |
| C5 D1 | 29.020 ± 4.257 | 30.255 ± 3.668 |
| C6 D1 | 28.574 ± 4.674 | 29.153 ± 4.009 |
| C7 D1 | 28.568 ± 4.548 | 29.523 ± 4.051 |
| C8 D1 | 28.557 ± 4.308 | 30.296 ± 3.890 |
| C9 D1 | 28.817 ± 4.665 | 30.186 ± 4.392 |
| C10 D1 | 29.057 ± 4.484 | 30.364 ± 4.143 |
| C11 D1 | 29.146 ± 4.207 | 30.688 ± 3.926 |
| C12 D1 | 29.648 ± 3.752 | 30.727 ± 3.896 |
| C13 D1 | 29.545 ± 4.056 | 31.483 ± 3.602 |
| C14 D1 | 29.579 ± 4.186 | 31.027 ± 3.790 |
| C15 D1 | 29.859 ± 4.438 | 30.730 ± 3.724 |
| C16 D1 | 29.683 ± 4.242 | 31.515 ± 3.242 |
| C17 D1 | 29.564 ± 4.695 | 31.567 ± 3.884 |
| C18 D1 | 29.380 ± 4.752 | 31.107 ± 4.425 |
| C19 D1 | 29.737 ± 4.414 | 31.417 ± 3.911 |
| C20 D1 | 29.844 ± 4.527 | 30.762 ± 4.122 |
| C21 D1 | 30.889 ± 3.115 | 30.056 ± 4.372 |
| C22 D1 | 31.696 ± 3.081 | 31.000 ± 3.275 |
| C23 D1 | 31.357 ± 3.388 | 31.143 ± 4.413 |
| End of treatment | 26.556 ± 5.487 | 26.786 ± 5.982 |
| Follow-up | 26.805 ± 6.373 | 26.769 ± 6.095 |
FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).
| units on a scale | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|
| C1 D1 | 31.020 ± 3.986 | 31.489 ± 4.538 |
| C2 D1 | 30.600 ± 3.892 | 30.682 ± 3.895 |
| C3 D1 | 30.645 ± 3.681 | 30.965 ± 3.803 |
| C4 D1 | 30.103 ± 4.558 | 30.679 ± 3.980 |
| C5 D1 | 30.676 ± 4.271 | 31.063 ± 3.629 |
| C6 D1 | 30.731 ± 3.973 | 31.439 ± 4.249 |
| C7 D1 | 30.920 ± 4.373 | 30.632 ± 4.365 |
| C8 D1 | 30.966 ± 4.144 | 30.703 ± 5.195 |
| C9 D1 | 31.012 ± 3.783 | 30.667 ± 4.884 |
| C10 D1 | 30.986 ± 4.133 | 30.926 ± 4.215 |
| C11 D1 | 31.212 ± 4.033 | 32.045 ± 3.579 |
| C12 D1 | 31.356 ± 3.443 | 32.000 ± 3.338 |
| C13 D1 | 31.418 ± 3.775 | 32.100 ± 2.989 |
| C14 D1 | 32.100 ± 3.321 | 32.800 ± 2.274 |
| C15 D1 | 32.000 ± 2.861 | 32.769 ± 2.279 |
| C16 D1 | 31.921 ± 3.372 | 33.167 ± 2.167 |
| C17 D1 | 32.061 ± 3.344 | 32.800 ± 2.898 |
| C18 D1 | 31.931 ± 3.116 | 32.625 ± 2.615 |
| C19 D1 | 32.364 ± 2.341 | 32.429 ± 4.429 |
| C20 D1 | 31.905 ± 2.998 | 33.500 ± 2.168 |
| C21 D1 | 33.125 ± 2.473 | 33.500 ± 2.345 |
| End of treatment | 28.216 ± 5.662 | 29.519 ± 4.661 |
| Follow-up | 24.692 ± 4.366 | 27.500 ± 6.762 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
| units on a scale | Axitinib (First-line Participants) | Sorafenib (First-line Participants) |
|---|---|---|
| C1 D1 | 0.710 ± 0.254 | 0.712 ± 0.272 |
| C2 D1 | 0.709 ± 0.214 | 0.693 ± 0.237 |
| C3 D1 | 0.694 ± 0.251 | 0.687 ± 0.261 |
| C4 D1 | 0.696 ± 0.235 | 0.668 ± 0.265 |
| C5 D1 | 0.708 ± 0.221 | 0.673 ± 0.269 |
| C6 D1 | 0.683 ± 0.263 | 0.641 ± 0.281 |
| C7 D1 | 0.685 ± 0.225 | 0.676 ± 0.255 |
| C8 D1 | 0.678 ± 0.274 | 0.717 ± 0.244 |
| C9 D1 | 0.704 ± 0.239 | 0.729 ± 0.202 |
| C10 D1 | 0.682 ± 0.277 | 0.723 ± 0.238 |
| C11 D1 | 0.698 ± 0.260 | 0.748 ± 0.199 |
| C12 D1 | 0.708 ± 0.227 | 0.742 ± 0.218 |
| C13 D1 | 0.708 ± 0.253 | 0.761 ± 0.220 |
| C14 D1 | 0.703 ± 0.260 | 0.731 ± 0.254 |
| C15 D1 | 0.689 ± 0.269 | 0.755 ± 0.225 |
| C16 D1 | 0.702 ± 0.244 | 0.775 ± 0.186 |
| C17 D1 | 0.706 ± 0.250 | 0.738 ± 0.250 |
| C18 D1 | 0.699 ± 0.259 | 0.777 ± 0.191 |
| C19 D1 | 0.713 ± 0.256 | 0.762 ± 0.261 |
| C20 D1 | 0.699 ± 0.261 | 0.710 ± 0.300 |
| C21 D1 | 0.712 ± 0.232 | 0.702 ± 0.307 |
| C22 D1 | 0.737 ± 0.255 | 0.774 ± 0.177 |
| C23 D1 | 0.736 ± 0.275 | 0.789 ± 0.187 |
| End of treatment | 0.635 ± 0.268 | 0.588 ± 0.291 |
| Follow-up | 0.545 ± 0.434 | 0.618 ± 0.254 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
| units on a scale | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|
| C1 D1 | 0.812 ± 0.225 | 0.831 ± 0.186 |
| C2 D1 | 0.769 ± 0.218 | 0.754 ± 0.251 |
| C3 D1 | 0.772 ± 0.206 | 0.755 ± 0.278 |
| C4 D1 | 0.737 ± 0.272 | 0.759 ± 0.211 |
| C5 D1 | 0.780 ± 0.203 | 0.768 ± 0.275 |
| C6 D1 | 0.767 ± 0.251 | 0.753 ± 0.245 |
| C7 D1 | 0.762 ± 0.252 | 0.768 ± 0.239 |
| C8 D1 | 0.758 ± 0.241 | 0.733 ± 0.339 |
| C9 D1 | 0.796 ± 0.203 | 0.794 ± 0.262 |
| C10 D1 | 0.768 ± 0.243 | 0.820 ± 0.169 |
| C11 D1 | 0.792 ± 0.210 | 0.848 ± 0.158 |
| C12 D1 | 0.797 ± 0.201 | 0.837 ± 0.157 |
| C13 D1 | 0.786 ± 0.217 | 0.814 ± 0.156 |
| C14 D1 | 0.833 ± 0.162 | 0.871 ± 0.131 |
| C15 D1 | 0.819 ± 0.151 | 0.829 ± 0.152 |
| C16 D1 | 0.811 ± 0.186 | 0.828 ± 0.142 |
| C17 D1 | 0.834 ± 0.158 | 0.865 ± 0.122 |
| C18 D1 | 0.830 ± 0.164 | 0.829 ± 0.160 |
| C19 D1 | 0.830 ± 0.148 | 0.861 ± 0.139 |
| C20 D1 | 0.832 ± 0.163 | 0.923 ± 0.129 |
| C21 D1 | 0.859 ± 0.155 | 0.852 ± 0.176 |
| End of treatment | 0.582 ± 0.406 | 0.623 ± 0.296 |
| Follow-up | 0.429 ± 0.358 | 0.418 ± 0.565 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.
| units on a scale | Axitinib (First-line Participants) | Sorafenib (First-line Participants) |
|---|---|---|
| C1 D1 | 71.181 ± 19.641 | 72.362 ± 16.466 |
| C2 D1 | 71.714 ± 16.583 | 72.422 ± 14.576 |
| C3 D1 | 72.006 ± 16.971 | 71.241 ± 16.252 |
| C4 D1 | 72.179 ± 16.980 | 72.086 ± 14.904 |
| C5 D1 | 72.451 ± 18.237 | 73.615 ± 14.665 |
| C6 D1 | 71.574 ± 18.929 | 69.944 ± 17.535 |
| C7 D1 | 71.050 ± 18.967 | 73.923 ± 13.998 |
| C8 D1 | 71.031 ± 19.081 | 73.183 ± 16.674 |
| C9 D1 | 72.690 ± 18.789 | 73.780 ± 16.180 |
| C10 D1 | 72.910 ± 19.354 | 72.400 ± 18.814 |
| C11 D1 | 72.763 ± 18.174 | 72.271 ± 18.512 |
| C12 D1 | 73.610 ± 18.275 | 75.295 ± 17.052 |
| C13 D1 | 73.030 ± 18.348 | 75.432 ± 17.907 |
| C14 D1 | 73.147 ± 17.546 | 75.108 ± 18.371 |
| C15 D1 | 74.494 ± 17.938 | 74.405 ± 17.650 |
| C16 D1 | 73.878 ± 18.289 | 75.818 ± 17.716 |
| C17 D1 | 73.090 ± 17.717 | 74.333 ± 18.654 |
| C18 D1 | 73.817 ± 17.288 | 75.571 ± 18.550 |
| C19 D1 | 72.089 ± 18.169 | 75.125 ± 20.919 |
| C20 D1 | 74.244 ± 17.044 | 74.190 ± 20.425 |
| C21 D1 | 75.694 ± 11.918 | 70.500 ± 21.637 |
| C22 D1 | 78.000 ± 12.544 | 73.917 ± 15.900 |
| C23 D1 | 77.143 ± 12.697 | 72.571 ± 14.820 |
| End of treatment | 67.254 ± 19.495 | 67.048 ± 22.570 |
| Follow-up | 69.195 ± 20.366 | 64.885 ± 19.916 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.
| units on a scale | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|
| C1 D1 | 82.799 ± 13.351 | 82.058 ± 14.021 |
| C2 D1 | 81.102 ± 13.895 | 78.231 ± 15.823 |
| C3 D1 | 80.895 ± 13.387 | 80.534 ± 16.453 |
| C4 D1 | 81.138 ± 13.508 | 81.245 ± 14.590 |
| C5 D1 | 83.018 ± 12.829 | 80.250 ± 15.495 |
| C6 D1 | 82.222 ± 13.793 | 80.829 ± 15.091 |
| C7 D1 | 82.900 ± 13.287 | 80.868 ± 16.140 |
| C8 D1 | 83.382 ± 12.636 | 81.000 ± 14.606 |
| C9 D1 | 84.171 ± 11.260 | 83.788 ± 10.349 |
| C10 D1 | 83.041 ± 13.042 | 82.778 ± 11.440 |
| C11 D1 | 84.136 ± 14.231 | 83.000 ± 11.832 |
| C12 D1 | 84.305 ± 13.211 | 83.500 ± 12.188 |
| C13 D1 | 82.927 ± 17.317 | 83.300 ± 11.263 |
| C14 D1 | 86.520 ± 10.831 | 86.667 ± 8.715 |
| C15 D1 | 85.841 ± 11.783 | 86.462 ± 8.678 |
| C16 D1 | 87.579 ± 10.391 | 86.083 ± 8.816 |
| C17 D1 | 88.424 ± 10.866 | 84.300 ± 10.328 |
| C18 D1 | 86.586 ± 13.605 | 83.125 ± 8.839 |
| C19 D1 | 89.500 ± 8.684 | 82.143 ± 11.495 |
| C20 D1 | 90.333 ± 8.679 | 86.000 ± 9.695 |
| C21 D1 | 90.313 ± 9.741 | 84.167 ± 9.704 |
| End of treatment | 75.568 ± 17.934 | 74.741 ± 17.623 |
| Follow-up | 58.154 ± 20.760 | 64.333 ± 25.564 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib (First-line Participants) | 117/173 (67.6%) | 77/173 (44.5%) | 161/173 (93.1%) |
| Sorafenib (First-line Participants) | 63/88 (71.6%) | 26/88 (29.5%) | 83/88 (94.3%) |
| Axitinib (Second-line Participants) | 9/11 (81.8%) | 6/11 (54.5%) | 11/11 (100%) |
| Sorafenib (Second-line Participants) | 3/5 (60%) | 3/5 (60%) | 5/5 (100%) |
| Event | Axitinib (First-line Participants) | Sorafenib (First-line Participants) | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/173 | 1/88 | 3/11 | 1/5 |
| Abdominal painGastrointestinal disorders | 1/173 | 3/88 | 2/11 | 1/5 |
| Anal fistulaGastrointestinal disorders | 1/173 | 0/88 | 0/11 | 1/5 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/173 | 0/88 | 0/11 | 1/5 |
| Anal abscessInfections and infestations | 0/173 | 0/88 | 0/11 | 1/5 |
| Axonal and demyelinating polyneuropathyNervous system disorders | 0/173 | 1/88 | 0/11 | 1/5 |
| Cardio-respiratory arrestCardiac disorders | 2/173 | 0/88 | 0/11 | 1/5 |
| PneumoniaInfections and infestations | 4/173 | 1/88 | 1/11 | 1/5 |
| Disease progressionGeneral disorders | 20/173 | 6/88 | 0/11 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 8/173 | 2/88 | 1/11 | 0/5 |
| Event | Axitinib (First-line Participants) | Sorafenib (First-line Participants) | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) |
|---|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 41/173 | 31/88 | 4/11 | 4/5 |
| DiarrhoeaGastrointestinal disorders | 88/173 | 34/88 | 6/11 | 2/5 |
| Back painMusculoskeletal and connective tissue disorders | 29/173 | 14/88 | 6/11 | 0/5 |
| ProteinuriaRenal and urinary disorders | 19/173 | 9/88 | 6/11 | 0/5 |
| HypertensionVascular disorders | 83/173 | 28/88 | 4/11 | 1/5 |
| Decreased appetiteMetabolism and nutrition disorders | 48/173 | 16/88 | 5/11 | 0/5 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 28/173 | 10/88 | 5/11 | 1/5 |
| AstheniaGeneral disorders | 41/173 | 15/88 | 5/11 | 0/5 |
| Weight decreasedInvestigations | 70/173 | 24/88 | 4/11 | 1/5 |
| FatigueGeneral disorders | 55/173 | 25/88 | 4/11 | 2/5 |
Full analysis set (FAS) included all treatment-naive participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.
| Age, Customized(Participants) | Axitinib (First-line Participants) | Sorafenib (First-line Participants) | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) | Total |
|---|---|---|---|---|---|
| Less than (<) 65 years | 142 | 77 | 110 | 56 | 385 |
| Greater than or equal to (>=) 65 years | 50 | 19 | 25 | 13 | 107 |
| Sex: Female, Male(Participants) | Axitinib (First-line Participants) | Sorafenib (First-line Participants) | Axitinib (Second-line Participants) | Sorafenib (Second-line Participants) | Total |
|---|---|---|---|---|---|
| Female | 58 | 22 | 41 | 20 | 141 |
| Male | 134 | 74 | 94 | 49 | 351 |
Showing the first 100 of 125 sites across 14 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Aug 2009 to primary completion in Jul 2012, 35 months.
Results were first posted in Feb 2014, 1 year 6 months after primary completion.
Of 22 phase 3 interventional studies under Kidney Neoplasms, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 89. This study's 35 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib